Neurocrine Biosciences, Inc. (NBIX)
164.63
+4.87
(+3.05%)
USD |
NASDAQ |
Nov 06, 16:00
164.65
+0.02
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Total Long Term Debt (Quarterly) : 392.30M for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 392.30M |
| June 30, 2026 | 401.80M |
| March 31, 2026 | 406.20M |
| December 31, 2025 | 415.30M |
| September 30, 2025 | 428.40M |
| June 30, 2025 | 439.10M |
| March 31, 2025 | 447.50M |
| December 31, 2024 | 455.10M |
| September 30, 2024 | 251.40M |
| June 30, 2024 | 256.20M |
| March 31, 2024 | 252.90M |
| December 31, 2023 | 428.40M |
| September 30, 2023 | 255.80M |
| June 30, 2023 | 258.80M |
| March 31, 2023 | 259.90M |
| December 31, 2022 | 262.90M |
| September 30, 2022 | 265.80M |
| June 30, 2022 | 268.60M |
| March 31, 2022 | 480.20M |
| December 31, 2021 | 440.40M |
| September 30, 2021 | 437.10M |
| June 30, 2021 | 435.30M |
| March 31, 2021 | 429.50M |
| December 31, 2020 | 412.30M |
| September 30, 2020 | 508.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 503.80M |
| March 31, 2020 | 499.70M |
| December 31, 2019 | 495.56M |
| September 30, 2019 | 478.07M |
| June 30, 2019 | 464.65M |
| March 31, 2019 | 460.58M |
| December 31, 2018 | 388.50M |
| September 30, 2018 | 383.65M |
| June 30, 2018 | 378.88M |
| March 31, 2018 | 374.21M |
| December 31, 2017 | 369.62M |
| September 30, 2017 | 365.11M |
| June 30, 2017 | 360.68M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Amgen, Inc. | 54.01B |
| Halozyme Therapeutics, Inc. | 3.250B |
| BioCryst Pharmaceuticals, Inc. | 825.78M |
| Iovance Biotherapeutics, Inc. | 42.77M |
| Precigen, Inc. | 97.47M |